These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38899217)

  • 1. Response to Letter to the Editor From Bouwmeester RN et al.: "Eculizumab in Postransplant TMA: Unproven Benefit.".
    Maritati F; La Manna G; Comai G
    Kidney Int Rep; 2024 Jun; 9(6):1930-1931. PubMed ID: 38899217
    [No Abstract]   [Full Text] [Related]  

  • 2. Eculizumab in Posttransplant TMA: Unproven Benefit: A Response to Maritati et al.: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.
    Bouwmeester RN; Wetzels JFM; van de Kar NCAJ
    Kidney Int Rep; 2024 Jun; 9(6):1929. PubMed ID: 38899173
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
    Schoettler M; Lehmann L; Li A; Ma C; Duncan C
    Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
    Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature.
    Zafar A; Lim MY; Abou-Ismail MY
    Thromb Res; 2023 Apr; 224():73-79. PubMed ID: 36871347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to Letter to the Editor From Ville S. et al. About: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.
    Maritati F; La Manna G; Comai G
    Kidney Int Rep; 2024 Jun; 9(6):1933-1934. PubMed ID: 38899194
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab.
    Wada H; Teranishi H; Shimono A; Kato N; Maruyama S; Matsumoto M
    Thromb J; 2023 Apr; 21(1):43. PubMed ID: 37072821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
    Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
    Front Immunol; 2020; 11():564647. PubMed ID: 33552043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy.
    Gomez-Ganda L; Benitez-Carabante MI; Fernandez-Polo A; Muñoz-Lopez M; Renedo-Miro B; Ariceta G; Diaz De Heredia C
    Front Pediatr; 2021; 9():761726. PubMed ID: 34858907
    [No Abstract]   [Full Text] [Related]  

  • 10. Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
    Ito S; Saito A; Sakurai A; Watanabe K; Karakawa S; Miyamura T; Yokosuka T; Ueki H; Goto H; Yagasaki H; Kinoshita M; Ozeki M; Yokoyama N; Teranishi H
    Bone Marrow Transplant; 2024 Mar; 59(3):315-324. PubMed ID: 38102212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes.
    Ariceta G; Fakhouri F; Sartz L; Miller B; Nikolaou V; Cohen D; Siedlecki AM; Ardissino G
    Clin Kidney J; 2021 Sep; 14(9):2075-2084. PubMed ID: 35261761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
    Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study.
    Menne J; Delmas Y; Fakhouri F; Kincaid JF; Licht C; Minetti EE; Mix C; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
    Clin Kidney J; 2019 Apr; 12(2):196-205. PubMed ID: 30976396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
    Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
    Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.
    Macia M; de Alvaro Moreno F; Dutt T; Fehrman I; Hadaya K; Gasteyger C; Heyne N
    Clin Kidney J; 2017 Jun; 10(3):310-319. PubMed ID: 28621343
    [No Abstract]   [Full Text] [Related]  

  • 18. Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma.
    Shimizu S; Morohashi T; Kanezawa K; Yagasaki H; Takahashi S; Morioka I
    Front Pediatr; 2022; 10():908183. PubMed ID: 35859949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab-Associated Thrombotic Microangiopathy Treated with Eculizumab: A Case Report.
    Padilha WSC; Cesar BN; Pacheco ST; De Sousa AA; Ledesma FL; Malheiros DMAC; Teixeira MCA
    Am J Case Rep; 2023 Aug; 24():e940906. PubMed ID: 37644709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.